World changing innovation isn’t something you hear about every day. But when you listen to the Vicor Powering Innovation podcast, you can be the first to learn how Vicor’s novel approach to power unlocks the potential of world-changing technologies. Outside-the-box thinking backed by sophisticated engineering discipline has proven to be the formula for success. Our special guests share what they have achieved in their industry and offer some behind-the-scenes engineering insights that enable ...
…
continue reading
Vicor Podcasts
Biotech2050 Podcast is a think tank chronicling the disruptions changing the biotech industry over the next 50 years.
…
continue reading

1
Ahmed Mousa, Vicore CEO, on IPF Breakthroughs, AI-Powered Drug Discovery & Global Biotech Leadership
16:33
16:33
Play later
Play later
Lists
Like
Liked
16:33Synopsis: What do courtroom litigation, computational biology, and fibrosis drug development have in common? In this episode of Biotech 2050, host Alok Tayi speaks with Ahmed Mousa, CEO of Vicore Pharma, to explore his unconventional journey from biotech law to the C-suite. Ahmed shares how Vicore is advancing a first-in-class therapy targeting the…
…
continue reading

1
Curran Simpson, President & CEO of REGENXBIO, on Gene Therapy, Strategy & Patient-Centered Impact
28:19
28:19
Play later
Play later
Lists
Like
Liked
28:19Synopsis: When an introverted engineer becomes the President & CEO of REGENXBIO, transformation follows. Curran Simpson joins host Rahul Chaturvedi to unpack his unlikely journey from biotech operations to the C-suite—and how that hands-on experience is reshaping gene therapy's future.They dive into the evolution of REGENXBIO’s pipeline, tackling u…
…
continue reading

1
Sergey Jakimov, Founding Partner at LongeVC, on Pragmatic Longevity Investing & Biotech Innovation
31:50
31:50
Play later
Play later
Lists
Like
Liked
31:50Synopsis: Longevity isn’t just about living longer—it’s about living better. In this insightful episode of Biotech 2050, host Alok Tayi sits down with Sergey Jakimov, Founding Partner at LongeVC, to unpack what it really takes to invest in the future of healthspan.Blending his experience as a medtech entrepreneur, rare disease patient, and venture …
…
continue reading

1
Dr. Howard Fillit & Mark Roithmayr of ADDF on Alzheimer’s Innovation, Funding & Biomarkers
41:51
41:51
Play later
Play later
Lists
Like
Liked
41:51Synopsis:What happens when a world-class scientist and a philanthropic legacy collide with one of medicine’s greatest challenges? Dr. Howard Fillit and Mark Roithmayr of the Alzheimer’s Drug Discovery Foundation (ADDF) join host Alok Tayi for an inspiring conversation on bold science, visionary funding models, and the future of Alzheimer’s research…
…
continue reading

1
Stacy Lindborg, Imunon President & CEO, on Bold Biotech, IL-12 Immunotherapy & Phase 3 Trials
17:54
17:54
Play later
Play later
Lists
Like
Liked
17:54Synopsis: What does bold biotech leadership look like in 2025?In this episode of Biotech 2050, host Alok Tayi sits down with Stacy Lindborg, President & CEO of Imunon, to discuss bold innovation in ovarian cancer treatment and how harnessing the immune system through targeted gene therapy is reshaping survival outcomes.Stacy shares insights from he…
…
continue reading

1
Stephanie Sirota, CBO & Partner at RTW Investments, on Biotech Investing, Policy & Bold Bet Building
24:48
24:48
Play later
Play later
Lists
Like
Liked
24:48Synopsis: What happens when a former journalist becomes one of biotech’s boldest investors? Meet Stephanie Sirota, Chief Business Officer and Partner at RTW Investments, who helped grow the firm from $27 million in assets to a global biotech force. In this engaging conversation with host Rahul Chaturvedi, Stephanie shares her unconventional path in…
…
continue reading

1
Steve Tregay on Leading Mission BioCapital as Managing Partner & Fueling Early-Stage Biotech
41:54
41:54
Play later
Play later
Lists
Like
Liked
41:54Synopsis: Building in biotech isn’t for the faint of heart—especially during a market downturn. But that’s exactly when Steve Tregay, Managing Partner at Mission BioCapital, thrives. A seasoned entrepreneur and founder of Forma Therapeutics, Steven has navigated biotech’s toughest cycles—and emerged stronger each time.Hosted by Rahul Chaturvedi, th…
…
continue reading

1
Neil F. McFarlane, President & CEO of Zevra Therapeutics, on Leading Rare Disease Innovation
35:35
35:35
Play later
Play later
Lists
Like
Liked
35:35Synopsis: In this episode of Biotech2050, host Rahul Chaturvedi sits down with Neil F. McFarlane, President and CEO of Zevra Therapeutics, to explore his unique leadership journey from military nurse to biotech executive. Neil shares reflections from his time at Genzyme and UCB, insights on running a rare disease-focused biotech, and the art of mis…
…
continue reading

1
Raj Devraj, President & CEO - Rectify Pharma, on Drug Discovery, Biotech Breakthroughs & Growth
34:03
34:03
Play later
Play later
Lists
Like
Liked
34:03Synopsis: How do you build a biotech company that disrupts drug discovery and delivers real impact? In this episode of Biotech 2050, host Rahul Chaturvedi speaks with Raj Devraj, President & CEO of Rectify Pharmaceuticals and Venture Partner at Atlas Venture.Raj shares his journey from big pharma to biotech entrepreneurship, the science behind Rect…
…
continue reading

1
Revolutionizing CAR T with CRISPR: Rachel Haurwitz, President & CEO of Caribou Biosciences
26:25
26:25
Play later
Play later
Lists
Like
Liked
26:25Synopsis: Host Rahul Chaturvedi welcomes back Rachel Haurwitz, President & CEO of Caribou Biosciences, for a deep dive into the future of CRISPR-based genome editing and its transformative impact on cell therapy. As a pioneer in the field, Rachel shares the evolution of off-the-shelf CAR T therapies and how Caribou Biosciences is tackling some of t…
…
continue reading

1
Liam Killingstad on How Family Offices Quietly Fuel Biotech’s Boldest Innovations
59:19
59:19
Play later
Play later
Lists
Like
Liked
59:19Synopsis: In this thought-provoking episode of Biotech 2050, host Alok Tayi sits down with Liam Killingstad, Member at Finiam Investments, to unpack the growing influence of family offices in biotech. Driven by his own family's experience with rare cancers, Liam shares how that journey sparked Finiam's deep dive into biotech investing and the co-cr…
…
continue reading

1
Clare Terlouw, Head of LifeArc Ventures, on Bridging Biotech’s Funding Gap & Investing for Impact
42:53
42:53
Play later
Play later
Lists
Like
Liked
42:53Synopsis: Host Alok Tayi sits down with Clare Terlouw, Head of Ventures at LifeArc Ventures, to explore biotech investing from an LP perspective. Clare shares her unique journey—from physiotherapy to investment banking and, ultimately, leading venture investments at a medical charity. The conversation delves into LifeArc’s role in bridging the fund…
…
continue reading

1
AI, Biotech, & Venture Capital: Alex Bangash, Founder of Transpose, on Future of Startup Investing
23:49
23:49
Play later
Play later
Lists
Like
Liked
23:49Synopsis: Venture capital is evolving, and so is biotech. In this episode of Biotech 2050, host Alok Tayi, CEO and co-founder of VibeBio, sits down with Alex Bangash, Founder of Transpose, an investment firm backing both startups and funds.With over 20 years of experience in venture investing, Alex shares his unconventional journey from engineering…
…
continue reading

1
Empowering Neurodivergent Innovators: Chad Belinsky on Impact, Mentorship, and Atypical Path
35:35
35:35
Play later
Play later
Lists
Like
Liked
35:35Synopsis: In this special episode of Biotech 2050, Host Alok Tayi, CEO and Co-Founder of VibeBio, delves into the world of neurodivergent entrepreneurship and impact investing with guest Chad Belinsky, founder of AtypicalPath.org. Chad shares his inspiring journey from running a transformative B2B materials company to establishing Atypical Path—a n…
…
continue reading

1
Biotech Venture Investing with Narayan Chowdhury, Co-Founder of Franklin Park LLC
27:32
27:32
Play later
Play later
Lists
Like
Liked
27:32Synopsis: In this episode of Biotech 2050, host Alok Tayi explores the world of biotech venture capital with Narayan Chowdhury, Co-Founder of Franklin Park. As a key player in funding the next wave of biotech breakthroughs, Narayan shares how limited partners (LPs) navigate risk, identify high-potential biotech funds, and decide where to allocate b…
…
continue reading

1
David Meeker, CEO of Rhythm Pharmaceuticals, on Rare Disease Breakthroughs & Biotech’s Future
58:17
58:17
Play later
Play later
Lists
Like
Liked
58:17Synopsis: Join host Alok Tayi as he welcomes David Meeker, CEO of Rhythm Pharmaceuticals, for an inspiring conversation on the transformative journey of rare disease biotech. David shares his incredible path from practicing physician to biotech visionary, recounting his experiences at Genzyme, where he helped shape the rare disease business model a…
…
continue reading

1
Pioneering Advances in Cell Therapy: Kristin Yarema, President & CEO of Poseida Therapeutics
38:57
38:57
Play later
Play later
Lists
Like
Liked
38:57Synopsis: Host Rahul Chaturvedi leads an insightful conversation with Dr. Kristin Yarema, President and CEO of Poseida Therapeutics. Kristin shares the inspiring journey of her career, from her roots in science to leadership roles in big pharma, culminating in her move to biotech entrepreneurship. She reflects on pivotal experiences at Novartis and…
…
continue reading

1
Bharatt Chowrira, CEO & Eric Elenko, CoFounder & President of PureTech on Biotech Growth
44:44
44:44
Play later
Play later
Lists
Like
Liked
44:44Synopsis: In this insightful conversation on Biotech2050, host Rahul Chaturvedi sits down with Bharatt Chowrira, CEO, and Eric Elenko, Co-Founder and President of PureTech Health. They explore the company’s pioneering R&D model and how it reshapes drug development by focusing on solving specific problems rather than pushing predefined solutions. Bh…
…
continue reading

1
Rob Williamson, CEO of Triumvira, on Biotech’s High-Stakes Path and Cell Therapy Innovations
23:45
23:45
Play later
Play later
Lists
Like
Liked
23:45Synopsis: Rob Williamson, CEO of Triumvira, joins Biotech 2050 host, Rahul Chaturvedi, to discuss his dynamic career from economics to biotech, tackling the volatile capital markets, and navigating high-stakes decisions in cell therapy. He shares insights on therapeutic developments in cell therapy, the pressures of solid tumor research, and the ev…
…
continue reading

1
Gene Mack, Interim CEO & CFO of Gain Therapeutics: Leading the Charge in Parkinson's Breakthroughs
32:01
32:01
Play later
Play later
Lists
Like
Liked
32:01Biotech2050 Host, Rahul Chaturvedi, engages with Gene Mack, Interim CEO and CFO of Gain Therapeutics, as he shares his journey from aspiring neurosurgeon to biotech leader. Gene reflects on his career shift from clinical research to Wall Street and eventually operational roles in biotech. He details the development of Gain's lead asset, GT02287, wh…
…
continue reading

1
Revolutionizing Heart Health: Bitterroot Bio’s Bold Vision with CEO Pavan Cheruvu
43:07
43:07
Play later
Play later
Lists
Like
Liked
43:07Synopsis: Discover how Bitterroot Bio is poised to revolutionize cardiovascular health in this captivating conversation between host Rahul Chaturvedi and CEO Pavan Cheruvu. Pavan opens up about his inspiring journey from engineering to leading a biotech company at the forefront of cardio-immunology. Learn how his visionary leadership is driving inn…
…
continue reading

1
Inside the Journey of Abcuro: CEO Alex Martin on Leadership, IBM, and the Future of Biotech
36:58
36:58
Play later
Play later
Lists
Like
Liked
36:58Synopsis: In this episode of Biotech 2050, Alex Martin, CEO of Abcuro, sits down with host Rahul Chaturvedi to share his inspiring journey from aspiring actor to biotech trailblazer. Alex reveals how his unique background shaped his leadership approach as he drives Abcuro’s groundbreaking work on Inclusion Body Myositis (IBM), a rare muscle disease…
…
continue reading

1
Precision Neuroscience Breakthroughs: Abe Ceesay, CEO of Rapport Therapeutics I Future of Biotech
47:12
47:12
Play later
Play later
Lists
Like
Liked
47:12Synopsis: Abe Ceesay, CEO of Rapport Therapeutics, sits down with host Rahul Chaturvedi to reveal how precision neuroscience is driving revolutionary treatments for neurological disorders. They explore Rapport’s cutting-edge lead program targeting focal epilepsy and discuss the groundbreaking advancements that are reshaping the landscape of drug de…
…
continue reading

1
Dr. Dave Bearss, Co-Founder & CEO of Halia, on Pioneering Genetic Discoveries to Defeat Alzheimer’s
35:36
35:36
Play later
Play later
Lists
Like
Liked
35:36Synopsis: Explore the forefront of biotech innovation as host Rahul Chaturvedi interviews Dr. Dave Bearss, Co-Founder & CEO of Halia Therapeutics, in this engaging episode of Biotech 2050. Dr. Bearss shares the story behind Halia’s pioneering genetic discoveries and their mission to tackle Alzheimer’s disease. Learn about the science driving breakt…
…
continue reading

1
Breaking Biotech Barriers: Avidity President & CEO Sarah Boyce on RNA’s Next Frontier
35:08
35:08
Play later
Play later
Lists
Like
Liked
35:08Synopsis: In this episode, host Rahul Chaturvedi interviews Sarah Boyce, President & CEO of Avidity Biosciences, as she shares her dynamic journey from big pharma to leading groundbreaking advancements in RNA therapeutics. Sarah delves into overcoming drug delivery challenges, the transformative potential of genetic medicine, and Avidity’s mission …
…
continue reading

1
Advancing Drug Discovery with Cutting-Edge AI & Team Synergy: Fabrice Chouraqui, CEO of Cellarity
31:40
31:40
Play later
Play later
Lists
Like
Liked
31:40Synopsis:Step into the future of biotech as host Rahul Chaturvedi delves into an exclusive conversation with Fabrice Chouraqui, CEO of Cellarity, as he unveils the groundbreaking ways AI is revolutionizing drug discovery. Fabrice will take you behind the scenes of Cellarity’s trailblazing approach, revealing how their pioneering technology is accel…
…
continue reading

1
Redefining Dementia Care: CervoMed's Bold Journey with CEO John Alam
24:38
24:38
Play later
Play later
Lists
Like
Liked
24:38Synopsis:Get ready for an insightful conversation as host Rahul Chaturvedi connects with John Alam, CEO of CervoMed, to uncover the revolutionary advancements transforming dementia treatment, with a spotlight on Dementia with Lewy Bodies (DLB). John shares his remarkable journey from practicing medicine to leading cutting-edge biotech innovations, …
…
continue reading

1
From Banking to Biotech: Renée Aguiar-Lucander, CEO of Calliditas, on Rare Disease Innovation
30:51
30:51
Play later
Play later
Lists
Like
Liked
30:51Synopsis:Renée Aguiar-Lucander, CEO of Calliditas Therapeutics, appears on this insightful episode of Biotech 2050 with host Rahul Chaturvedi. Renée shares her unconventional journey from investment banking to biotech leadership, underscoring the crucial role of capital markets and regulatory strategies. The discussion explores the unique challenge…
…
continue reading

1
Autoimmune Innovations: Insights from Marshall Fordyce, Founder & CEO, Vera Therapeutics on Biotech
32:50
32:50
Play later
Play later
Lists
Like
Liked
32:50Synopsis: In this engaging episode, host, Rahul Chaturvedi welcomes Marshall Fordyce, Founder and CEO of Vera Therapeutics, to discuss his transformative journey from physician to biotech entrepreneur. Marshall shares the story behind Vera Therapeutics' strategic pivot to focus on IG nephropathy and their development of atacicept, a promising B-cel…
…
continue reading

1
From toys to construction site tools, OLogic brings robotic ideas to life
26:35
26:35
Play later
Play later
Lists
Like
Liked
26:35Special Guest: Ted Larson, CEO of OLogic, a robotics design shop in California. Ted, a veteran of the robotics industry, has seen it grow from its infancy to today’s growth explosion. He shares the story behind OLogic’s growth and their role in developing some of today’s most innovative robots for local and national brands. Larson shares how the co…
…
continue reading

1
Next generation hydrogen powered drones are doing search and rescue, saving lives
14:34
14:34
Play later
Play later
Lists
Like
Liked
14:34Special Guest: Soon-Suk Roh, Director of Business Development from Doosan Mobility (South Korea). Soon-Suk shares the story behind developing the world’s first commercialized hydrogen fuel cell power pack for UAVs. Soon-Suk details the amazing duration of their UAVs and the humanitarian missions they fly providing relief to people in distress. By m…
…
continue reading

1
The future of long-haul trucking is accelerating autonomously on a freeway near you
33:11
33:11
Play later
Play later
Lists
Like
Liked
33:11Podcast host Robert Gendron, Corporate Vice President, Product Development Special Guest: Jamie Hoffacker, VP of Hardware at Kodiak Robotics, in Mountainview, CA. Kodiak is the leader in autonomous trucking. Their mission is to carry freight forward— so people, partners, and the planet thrive. They are evangelizing autonomous trucking and believe w…
…
continue reading

1
Transforming Gene Therapy: Exclusive Insights from Zandy Forbes, President & CEO of MeiraGTx
50:25
50:25
Play later
Play later
Lists
Like
Liked
50:25Synopsis:Zandy Forbes, Founder, President, and CEO of MeiraGTx, joins host Rahul Chaturvedi in this compelling episode. Zandy shares her inspiring journey from academia, where she developed a deep interest in molecular biology and genetics, to her significant role in biotech investing, and eventually leading a groundbreaking gene therapy company. S…
…
continue reading

1
Biotech Breakthroughs: Jeb Keiper, CEO of Nimbus Therapeutics, Discusses Their Innovative Journey
35:03
35:03
Play later
Play later
Lists
Like
Liked
35:03Synopsis:Dive into this episode of Biotech 2050 where host Rahul Chaturvedi interviews Jeb Keiper, CEO of Nimbus Therapeutics. Discover Jeb's fascinating journey from MIT chemist to industry leader, and the unique strategies that have driven Nimbus's success. Jeb discusses the evolution of biotech financing, the importance of taking bold risks, and…
…
continue reading

1
Revolutionizing Proteomics: Sujal Patel, Co-Founder & CEO of Nautilus, on Drug Development
36:55
36:55
Play later
Play later
Lists
Like
Liked
36:55Synopsis:Sujal Patel, co-founder and CEO of Nautilus Biotechnology, discusses their innovative work in proteomics and its impact on drug development. Sujal shares his transition from tech to biotech, the formation of Nautilus with Parag Mallick, and their revolutionary approach using multi-affinity probes. The conversation highlights the importance…
…
continue reading

1
Exploring Neuroscience, Psychiatry, & Rare Diseases, Bruce Leuchter, President & CEO, Neurvati
51:22
51:22
Play later
Play later
Lists
Like
Liked
51:22Synopsis: In this episode of Biotech 2050, host Alok Tayi, CEO and co-founder of Vibe Bio, speaks with Dr. Bruce Leuchter, President and CEO of Neurvati Neuroscience. They discuss capital markets, neurology, psychiatry, and Neurvati's work in ultra-rare diseases. Dr. Leuchter shares his journey from clinical training to leadership at Neurvati. The …
…
continue reading

1
Transformative Oncology Innovations, Ken Keller, President & CEO, Daiichi Sankyo, Inc.
28:18
28:18
Play later
Play later
Lists
Like
Liked
28:18Synopsis: In this episode of BioTech 2050, Ken Keller, President and CEO of Daiichi Sankyo, Inc. provides an in-depth look into the company's transformation from a cardiovascular-focused organization to a leader in oncology. He discusses the groundbreaking advancements in antibody-drug conjugates (ADCs), particularly highlighting the success of the…
…
continue reading

1
Strategic Leadership and Autoimmune Breakthroughs, Praveen Tipimeni, CEO
34:03
34:03
Play later
Play later
Lists
Like
Liked
34:03Synopsis: In this episode of Biotech2050, Praveen Tipirneni, CEO of Morphic Therapeutics, shares insights on Morphic’s strategic IPO, the rising interest in autoimmune treatments, the journey of their alpha 4 beta 7 program, and maintaining a conservative yet opportunistic approach in biotech. He also discusses the importance of building a strong t…
…
continue reading

1
Innovative Approaches to Cancer Therapies, Robert Ang, President and CEO
30:09
30:09
Play later
Play later
Lists
Like
Liked
30:09Synopsis: In this episode of BioTech 2050, Robert Ang, CEO of Vor Bio, shares insights on the current state of cancer therapies and next-gen modalities. He discusses Vor Bio's work on shielded stem cell transplants and CAR T-cell therapies targeting hematologic malignancies like AML and MDS. Robert also talks about his experience serving on boards …
…
continue reading

1
Tech-Biotech Convergence, Growth, and Global Lessons, Vik Bajaj, Co-founder and CEO
31:05
31:05
Play later
Play later
Lists
Like
Liked
31:05Synopsis: In this episode of Biotech2050, Vik Bajaj, Co-founder and CEO of Foresite Labs, delves into the convergence of tech and biotech, hyper-growth phases in biotech companies, changes in finance and capital markets, and lessons from global healthcare systems, particularly the UK. He highlights the transformative potential of technology in biot…
…
continue reading

1
Advancing and Revolutionizing Sickle Cell Treatment, Ted Love, Chair and BOD
27:00
27:00
Play later
Play later
Lists
Like
Liked
27:00Synopsis: In this episode of Biotech2050, Dr. Ted Love, former CEO of Global Blood Therapeutics and Current Chairman of BIO, shares insights on sickle cell breakthroughs, transitioning from academia to research, navigating a tight funding environment, and protecting an innovative ecosystem to benefit patients.Biography:Dr. Ted Love is the chair of …
…
continue reading

1
Demystifying Drug Discovery, Ray Stevens, CEO, Structure Therapeutics
31:57
31:57
Play later
Play later
Lists
Like
Liked
31:57Synopsis: In this episode of the Biotech 2050 podcast, host Rahul Chaturvedi engages in a thought-provoking conversation with Ray Stevens, a prominent figure in the biotech industry who co-founded Structure Therapeutics. Ray's extensive experience and pivotal role in advancing structure-based drug discovery make him a compelling guest for biotech e…
…
continue reading

1
Navigating The Evolving Landscape of Inflammation Research, Scott Megaffin, CEO, Adiso Therapeutics
27:55
27:55
Play later
Play later
Lists
Like
Liked
27:55Synopsis: In this episode of Biotech2050, Scott Megaffin, CEO of Adiso Therapeutics, shares valuable insights on the challenges and opportunities in the biotech industry. His deep involvement in the pharmaceutical and biopharmaceutical sector has shaped his strategic approach to leadership and business management. Scott emphasizes the importance of…
…
continue reading

1
Biotech's Game Changers & Revolutionizing Therapeutics, Dr. Mammen, CEO, FogPharma
50:36
50:36
Play later
Play later
Lists
Like
Liked
50:36Synopsis: In this episode of the Biotech2050 podcast, Dr. Mathai Mammen, CEO of FogPharma, shares valuable insights into the future trends of the biotech industry and the development of peptide-based therapeutics. Dr. Mammen's extensive career trajectory, from academia to leading pharmaceutical organizations, provides a comprehensive understanding …
…
continue reading

1
From Pikes Peak to Bonneville Salt Flats, Lightning Motorcycles electric bike outpaces the combustion engine motorcycles
30:23
30:23
Play later
Play later
Lists
Like
Liked
30:23Podcast host David Krakauer, VP of Corporate Marketing and Channel Strategy Special Guest: Richard Hatfield, founder and CEO of Lightning Motorcycles Lightning Motorcycles, located in San Jose, California, is one of the leading electric motorcycle designers in the world. Richard Hatfield, founder and CEO of Lightning Motorcycles, vision for an elec…
…
continue reading

1
The Race to Cure Untreatable Cancers, Ken Galbraith, Chair and CEO, Zymeworks
40:37
40:37
Play later
Play later
Lists
Like
Liked
40:37Synopsis: In the recent episode of Biotech2050, Ken Galbraith, CEO of Zymeworks, shares profound insights into the biotech industry, leadership, and the complexities of developing innovative treatments for challenging cancers. Galbraith's accidental entry into biotech in 1987, despite lacking prior experience, led to his pivotal role in establishin…
…
continue reading

1
Innovation in Precision Therapies for CNS Diseases, Craig Chambliss, Co-Founder and CEO, Neurelis
36:41
36:41
Play later
Play later
Lists
Like
Liked
36:41Synopsis: In this episode of Biotech2050, host Alok Tayi engages in a profound conversation with Craig Chambliss, CEO and co-founder of Neurellis, delving into their strategic advancements in precision therapies for CNS diseases. Chambliss shares his journey, highlighting his finance and accounting background and pivotal roles in pharmaceutical com…
…
continue reading

1
Unlocking Genetic Medicine's Full Potential, Tuyen Ong, CEO, Ring Therapeutics
23:07
23:07
Play later
Play later
Lists
Like
Liked
23:07Synopsis: On the Biotech2050 podcast, Tuyen Ong, CEO at Ring Therapeutics and CEO partner at flagship pioneering, shared his journey from a medical background to leading innovative gene therapy companies, highlighting the importance of cross-disciplinary expertise in driving biotech advancements. His insights into the gene therapy landscape and the…
…
continue reading

1
Aging Biology and The Power of Human Data, Kristen Fortney, Co-Founder and CEO, BioAge
26:45
26:45
Play later
Play later
Lists
Like
Liked
26:45Synopsis: In a recent episode of Biotech2050, hosted by Alok Tayi, Kristen Fortney, CEO of BioAge, provides valuable insights into the evolving landscape of aging biology and the innovative approach BioAge is taking to identify therapeutic targets. Kristen's background in aging biology, genetics, and statistics underscores her expertise in the fiel…
…
continue reading

1
The Intersection Of Tech and Biotech, Chris Gibson, Co-Founder & CEO, Recursion
39:42
39:42
Play later
Play later
Lists
Like
Liked
39:42Synopsis: In this episode of the Biotech2050 podcast, Chris Gibson, the co-founder and CEO of Recursion, shares insights on the intersection of technology and biotech, emphasizing the importance of adaptability and diverse partnerships in driving innovation. Gibson's journey from pursuing an MD-PhD program with a focus on merging engineering and me…
…
continue reading